Comparative single‐cell RNA sequencing analysis of immune response to inactivated vaccine and natural SARS‐CoV‐2 infection

Author:

He Shuai12,Liu Shu‐Qiang2,Teng Xiang‐Yun3,He Jin‐Yong1,Liu Yang2,Gao Jia‐Hui1,Wu Yue1,Hu Wei1,Dong Zhong‐Jun4,Bei Jin‐Xin2,Xu Jian‐Hua13

Affiliation:

1. Medical Laboratory Center Shunde Hospital of Guangzhou University of Chinese Medicine Foshan China

2. State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China

3. Medical Laboratory Center Maoming Hospital of Guangzhou University of Chinese Medicine Maoming China

4. School of Medicine and Institute for Immunology Tsinghua University Beijing China

Abstract

AbstractUncovering the immune response to an inactivated SARS‐CoV‐2 vaccine (In‐Vac) and natural infection is crucial for comprehending COVID‐19 immunology. Here we conducted an integrated analysis of single‐cell RNA sequencing (scRNA‐seq) data from serial peripheral blood mononuclear cell (PBMC) samples derived from 12 individuals receiving In‐Vac compared with those from COVID‐19 patients. Our study reveals that In‐Vac induces subtle immunological changes in PBMC, including cell proportions and transcriptomes, compared with profound changes for natural infection. In‐Vac modestly upregulates IFN‐α but downregulates NF‐κB pathways, while natural infection triggers hyperactive IFN‐α and NF‐κB pathways. Both In‐Vac and natural infection alter T/B cell receptor repertoires, but COVID‐19 has more significant change in preferential VJ gene, indicating a vigorous immune response. Our study reveals distinct patterns of cellular communications, including a selective activation of IL‐15RA/IL‐15 receptor pathway after In‐Vac boost, suggesting its potential role in enhancing In‐Vac‐induced immunity. Collectively, our study illuminates multifaceted immune responses to In‐Vac and natural infection, providing insights for optimizing SARS‐CoV‐2 vaccine efficacy.

Funder

China Postdoctoral Science Foundation

National Natural Science Foundation of China

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3